15th Apr 2015 07:10
LONDON (Alliance News) - Motif Bio PLC on Wednesday said the US Food and Drug Administration has agreed to the proposed phase three clinical development programme for the iclaprim product, sending shares in partner Amphion Innovations PLC higher in early trade.
Motif said the phase three programme is designed to secure marketing approval for an intravenous formulation of iclaprim for the treatment of acute bacterial skin and skin structure infections.
The company said that assuming the necessary funds can be raised or a partnership deal secured, the first phase trial for the treatment will start in the second half of 2015.
Amphion Innovations, which owns a 44% stake in Motif, saw its shares boosted by the news, up 19% to 7.00 pence in early trade to be one of the best performers in the AIM All-Share. Motif Bio shares were up 12% to 33.10 pence, one of the best performers in the London Main Market.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
MTFB.LAMP.L